At CTS, we understand the impact converting to the Ortho viral marker platform has on your operations. As we get closer to our implementation date of January 11, 2021 we are committed to providing you information as it becomes available.
Package inserts for the new assays are now available. You can review them on the Communications page by clicking this link: Communications,
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
This is the first update to the original CTS communication distributed on July 6th. As previously co...